Hanall Biopharma Co (XKRX:009420) COGS-to-Revenue : 0.54 (As of Dec. 2023)

View and export this data going back to 1989. Start your Free Trial

What is Hanall Biopharma Co COGS-to-Revenue?

Hanall Biopharma Co's Cost of Goods Sold for the three months ended in Dec. 2023 was ₩17,023 Mil. Its Revenue for the three months ended in Dec. 2023 was ₩31,718 Mil.

Hanall Biopharma Co's COGS to Revenue for the three months ended in Dec. 2023 was 0.54.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Hanall Biopharma Co's Gross Margin % for the three months ended in Dec. 2023 was 46.33%.

Hanall Biopharma Co COGS-to-Revenue Historical Data

The historical data trend for Hanall Biopharma Co's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hanall Biopharma Co COGS-to-Revenue Chart

Hanall Biopharma Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

COGS-to-Revenue

Get a 7-Day Free Trial

0.42

0.43

0.41

0.44

Hanall Biopharma Co Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
COGS-to-Revenue	Get a 7-Day Free Trial															0.41	0.45	0.34	0.47	0.54

Hanall Biopharma Co COGS-to-Revenue Calculation

Hanall Biopharma Co's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	59737.57	/	134909.838
	=	0.44

Hanall Biopharma Co's COGS to Revenue for the quarter that ended in Dec. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	17022.715	/	31718.153
	=	0.54

Hanall Biopharma Co (XKRX:009420) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Hanall Biopharma Co's Gross Margin % for the three months ended in Dec. 2023 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	17022.715 / 31718.153
	=	46.33 %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Hanall Biopharma Co COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Hanall Biopharma Co's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Hanall Biopharma Co (XKRX:009420) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hanall Biopharma Co Ltd (XKRX:009420) » Definitions » COGS-to-Revenue

Traded in Other Exchanges

N/A

Address

12 Bongeunsa-ro 114-gil, Daewoong Building, 3rd Floor, Gangnam-gu, Seoul, KOR

Website

http://www.hanall.co.kr

Hanall Biopharma Co Ltd is a part of the healthcare sector. It is one of Korea's leading pharmaceutical companies and is focused on drug delivery, biotherapeutics, and new small molecule discovery. The company's scope comprises of ophthalmology, immunology, cardiovascular treatment and dermatology.

Hanall Biopharma Co (XKRX:009420) Headlines

No Headlines